Thomas J. Kowalski

I'll research this attorney before writing the summary.

Thomas J. Kowalski — Duane Morris LLP (New York)

Focus areas. Kowalski's practice is life-sciences and chemistry-centric rather than electronics- or standards-driven. He is a registered U.S. patent attorney (USPTO Reg. No. 32,147) who chairs the Life Sciences, Pharmaceuticals and Biotechnology Division of Duane Morris's Intellectual Property Practice Group. Firm and industry profiles describe work spanning biotechnology, diagnostics, vaccines and virology, immunology and antibodies, cell and gene therapies, CRISPR/genome engineering, plant varieties, medicinal chemistry and small molecules, plus medical apparatus and chemical patent litigation. His profile also lists Hatch-Waxman patent litigation as a recognized area, alongside prosecution, licensing, due diligence and trademark/design rights. His single tracked litigation matter is squarely in that lane: tau-protein blood-assay diagnostics for Alzheimer's disease.

Side preference. The tracked data shows one plaintiff-side appearance and no defendant-side appearances. That single case, however, is a defensive posture rather than true plaintiff-side enforcement: Kowalski represented Fujirebio Diagnostics, which was the target of infringement threats and filed a declaratory-judgment action of non-infringement, with Quanterix counterclaiming for infringement. His broader practice is characterized in firm materials as prosecution- and counseling-heavy, with litigation and contentious work as one component — so the one-sided count reflects a single representative matter, not a plaintiff/NPE specialization. It should not be read as a general pro-plaintiff practice.

Firm context. Kowalski is a partner in Duane Morris's New York office and has been for roughly four years; before that he practiced at Vedder Price, which he left in 2022 to lead a seven-lawyer IP group (with Deborah Lu) to Duane Morris. He is a long-tenured practitioner, having begun practice in 1986.

Notable tracked matter and outcomes. Fujirebio Diagnostics, Inc. v. Quanterix Corp. (D. Del. No. 1:25-cv-00659, Judge Gregory B. Williams) concerned U.S. Patent 11,275,092, directed to quantifying low-concentration tau protein in blood. Kowalski entered pro hac vice for Fujirebio; the firm also filed an IPR petition on Fujirebio's behalf. The Board denied institution of IPR2025-01060 on October 7, 2025, and terminated the proceeding (Petitioner's later filing sought refund of the unused post-institution fees). In the district court case, the parties stipulated to a stay in March 2026 pending finalization of a settlement, and the case was dismissed with prejudice under Fed. R. Civ. P. 41(a)(2) on April 10, 2026, each side bearing its own costs. No merits ruling issued on validity or infringement, so there is no verdict, Federal Circuit decision, or adjudicated outcome to report.

PTAB / IPR experience. His PTAB exposure is thin in the tracked record — a single IPR petition (IPR2025-01060, as backup counsel behind lead counsel Patrick D. McPherson) that was not instituted. Firm bios state that he has represented clients before the USPTO and the PTAB and in foreign contentious proceedings, including a patent nullity/opposition involving Merial and Intervet, but I found no verified pattern of regular IPR/PGR practice.

Bar and education. B.S. (ACS-certified chemistry), New York University, 1982; J.D. with honors, St. John's University School of Law, 1986. Admitted in New York (1987); U.S. Patent and Trademark Office; S.D.N.Y., E.D.N.Y. and W.D.N.Y.; U.S. Court of Appeals for the Federal Circuit; U.S. Supreme Court.

Caveat on sourcing: the tracked appearance list contains only one matter, so the side-preference and PTAB observations rest on a very small sample. Outcome details for the Fujirebio/Quanterix case are drawn from docket records and PTAB filings; the settlement terms themselves are not public beyond the dismissal stipulation.